Nana Muazin

A Legacy of Resilience: Sharsheret’s Year-End Appeal Honors Founder Rochelle Shoretz’s Vision

• Patient Advocacy and Support

A Legacy of Resilience: Sharsheret’s Year-End Appeal Honors Founder Rochelle Shoretz’s Vision

Nana Muazin July 18, 2026

By [Your Name/Journalist Name] December 1, 2025 TEANECK, N.J. — In the landscape of non-profit healthcare advocacy,...

Read More Read more about A Legacy of Resilience: Sharsheret’s Year-End Appeal Honors Founder Rochelle Shoretz’s Vision

From Shelters to Science: How Biotech Launch is Redefining the Workforce Pipeline

• Genomics and Precision Medicine

From Shelters to Science: How Biotech Launch is Redefining the Workforce Pipeline

Nana Muazin July 17, 2026

Executive Summary: Bridging the Opportunity Gap In the rapidly expanding landscape of Alabama’s biotechnology sector, a critical...

Read More Read more about From Shelters to Science: How Biotech Launch is Redefining the Workforce Pipeline

Four Years of 988: Assessing the Impact and Future of America’s Crisis Infrastructure

• Breast Cancer Legislation and Policy

Four Years of 988: Assessing the Impact and Future of America’s Crisis Infrastructure

Nana Muazin July 15, 2026

On July 16, 2022, the United States fundamentally shifted its approach to mental health emergencies with the...

Read More Read more about Four Years of 988: Assessing the Impact and Future of America’s Crisis Infrastructure

Beyond the Checkbook: Redefining Corporate Social Responsibility Through Gifts-in-Kind

• Survivorship and Post-Treatment

Beyond the Checkbook: Redefining Corporate Social Responsibility Through Gifts-in-Kind

Nana Muazin July 15, 2026

By Madison Decker, Charitable Advancement Manager, National Breast Cancer Foundation With contributions from Katie Mooneyham, Strategic Partnerships...

Read More Read more about Beyond the Checkbook: Redefining Corporate Social Responsibility Through Gifts-in-Kind

From Fear to Freedom: How One Family’s Genetic Legacy Transformed into a Lifesaving Strategy

• Survivorship and Post-Treatment

From Fear to Freedom: How One Family’s Genetic Legacy Transformed into a Lifesaving Strategy

Nana Muazin July 15, 2026

By Editorial Staff June 22, 2026 In the landscape of modern medicine, few revelations carry as much...

Read More Read more about From Fear to Freedom: How One Family’s Genetic Legacy Transformed into a Lifesaving Strategy

Biopharma Industry Update: Strategic Shifts, Clinical Breakthroughs, and Regulatory Milestones

• Treatment Innovations

Biopharma Industry Update: Strategic Shifts, Clinical Breakthroughs, and Regulatory Milestones

Nana Muazin July 14, 2026

By Ben Fidler | July 13, 2026 The biotechnology and pharmaceutical sectors continue to navigate a period...

Read More Read more about Biopharma Industry Update: Strategic Shifts, Clinical Breakthroughs, and Regulatory Milestones

Still Here, Still Fighting, Still Hopeful: Navigating the Realities of Advanced Ovarian Cancer

• Patient Advocacy and Support

Still Here, Still Fighting, Still Hopeful: Navigating the Realities of Advanced Ovarian Cancer

Nana Muazin July 13, 2026

By [Your Name/Journalist Name] May 8, 2026 The date May 8 marks World Ovarian Cancer Day, a...

Read More Read more about Still Here, Still Fighting, Still Hopeful: Navigating the Realities of Advanced Ovarian Cancer

Navigating the Storm: Guiding Children Through Cancer Recurrence with Honesty and Hope

• Patient Advocacy and Support

Navigating the Storm: Guiding Children Through Cancer Recurrence with Honesty and Hope

Nana Muazin July 12, 2026

Introduction: The Unforeseen Return The initial diagnosis of cancer is a seismic event for any family, a...

Read More Read more about Navigating the Storm: Guiding Children Through Cancer Recurrence with Honesty and Hope

Clinical Setbacks Terminate GSK-Alector Neuroscience Partnership

• Treatment Innovations

Clinical Setbacks Terminate GSK-Alector Neuroscience Partnership

Nana Muazin July 9, 2026

By Jacob Bell Published July 9, 2026 In a significant blow to its strategic pivot toward neurodegenerative...

Read More Read more about Clinical Setbacks Terminate GSK-Alector Neuroscience Partnership

British Pharma Giants Double Down on China Amid Growing Regulatory Scrutiny

• Chemotherapy and Targeted Therapy

British Pharma Giants Double Down on China Amid Growing Regulatory Scrutiny

Nana Muazin July 8, 2026

By Jonathan Gardner | Published July 8, 2026 In a strategic maneuver that highlights the persistent allure...

Read More Read more about British Pharma Giants Double Down on China Amid Growing Regulatory Scrutiny